Drug intelligence / Profile preview

CR002

Development stage: Unknown
Lead developer: Celldex Therapeutics
Modality: Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CR002 is a fully human monoclonal antibody that neutralizes platelet-derived growth factor D (PDGF-D), a protein implicated in the pathogenesis of kidney inflammation. By blocking PDGF-D, which stimulates mesangial cell proliferation and extracellular matrix accumulation, CR002 aims to treat nephropathies such as IgA nephropathy, lupus nephritis, and diabetic nephropathy. The drug was developed using XenoMouse technology and has demonstrated safety and tolerability in Phase I clinical trials. It has received Orphan Drug status from the US FDA for IgA nephropathy[1][3][4][5][9].

Other names: Human monoclonal antibody against platelet-derived growth factor D

Targets

PDGF (Platelet-derived Growth Factor family)

Beyond the preview

Go deeper on CR002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CR002.

Explore the full profile